An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

NCT01085266 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

362

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington Disease

Interventions

DRUG: Dimebon (latrepirdine)

Sponsor

Medivation, Inc.

Collaborators

[object Object]